Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

The next horizon in metastatic non-small cell targeted therapy

The optimal sequence: Does overall survival matter?

Date

30 Sep 2019

Session

The next horizon in metastatic non-small cell targeted therapy

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Tony S.K. Mok

Authors

T.S.K. Mok

Author affiliations

  • Clinical Oncology Department, Prince of Wales Hospital, Shatin/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Targeted KRAS mutation

Presenter: Pasi Jänne

Session: The next horizon in metastatic non-small cell targeted therapy

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.